Abstract
HIV(+) subjects on optimal antiretroviral therapy have persistently impaired antibody responses to pneumococcal vaccination. We explored the possibility that this effect may be due to HIV protease inhibitors (PIs). We found that in humans and mice, PIs do not affect antibody production in response to pneumococcal vaccination.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Publication types
-
Clinical Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies, Bacterial / biosynthesis*
-
Antibodies, Bacterial / blood
-
Antiretroviral Therapy, Highly Active / adverse effects
-
CD4 Lymphocyte Count
-
Female
-
HIV Infections / drug therapy
-
HIV Infections / immunology*
-
HIV Infections / virology
-
HIV Protease Inhibitors / adverse effects*
-
HIV Protease Inhibitors / therapeutic use
-
Humans
-
Immunoglobulin G / blood
-
Immunoglobulin M / blood
-
Male
-
Mice
-
Pneumococcal Infections / immunology
-
Pneumococcal Infections / microbiology
-
Pneumococcal Infections / prevention & control
-
Pneumococcal Vaccines / administration & dosage
-
Pneumococcal Vaccines / immunology*
-
Ritonavir / therapeutic use
-
Streptococcus pneumoniae / immunology*
-
Vaccination
Substances
-
Antibodies, Bacterial
-
HIV Protease Inhibitors
-
Immunoglobulin G
-
Immunoglobulin M
-
Pneumococcal Vaccines
-
Ritonavir